A unique technology improving solubility

As the global leader and pioneer with more than thirty-five years of HME extrusion development experience, AbbVie has launched the most commercial products utilizing this technology. HME is widely recognized as an effective technology to transform poorly soluble APIs into amorphous solid dispersions ultimately improving patient compliance and making the manufacturing process more efficient.

In this process, a powder of crystalline API and polymers is heated and extruded into a matrix with the API dispersed evenly throughout in the polymer matrix.  HME is a robust process that effectively addresses the need to enhance bioavailability of a poorly soluble APIs. The extrudate is then converted into granules or pellets in preparation for downstream processing into tablets, capsules or powder filled sachets.

Our unparalleled leadership in formulation and manufacturing, with more than 35 years of expertise, combined with academic collaborations that drive innovation, has resulted in the highest rate of HME technical publications, more than one hundred developed products and more than eight commercial products launched.

AbbVie Contract Manufacturing offers proprietary hot melt extrusion (HME) technology development, clinical and commercial manufacturing in both the US and Europe. 

AbbVie advances your science like we would our own, with customized pharmaceutical hot melt extrusion services that include: